BTIG Upgrades NeoGenomics to Buy, Announces $28 Price Target
10/6/2026
Impact: 70
Healthcare
BTIG analyst Mark Massaro has upgraded NeoGenomics (NASDAQ: NEO) from a Neutral rating to a Buy rating. The firm has set a price target of $28 for the stock.
AI summary, not financial advice
Share: